Publications by authors named "Konstantinos Fotiou"
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Andreas Pinter Kilian Eyerich Antonio Costanzo Alyssa Garrelts Christopher Schuster Konstantinos Fotiou
J Dermatolog Treat
December 2024
Purpose: Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoHO), is to provide evidence if early intervention with biologics is associated with better treatment outcomes and if there is any difference among drug classes or individual biologics.
Materials And Methods: For this post-hoc analysis patients were categorised into two subgroups according to shorter (≤2 years) or longer (>2 years) disease duration.
Article Synopsis
- Recent network meta-analyses (NMAs) were conducted to evaluate the effectiveness of biologic treatments for nail psoriasis, including newly approved drugs like bimekizumab, and provided data over periods of 24-28 and 48-52 weeks.
- The analyses showed that ixekizumab ranked highest in achieving complete nail resolution at both time points, followed by brodalumab and adalimumab.
- These findings can assist healthcare providers in making informed treatment choices for patients suffering from nail psoriasis.